Analysis Of Differentially Expressed Proteins In Sera Of Advanced Non-small Cell Lung Cancer Patients Responsive To Gemcitabine

Lung cancer has the highest incidence and mortality rates among all types of carcinoma. Of all patients of Lung cancer, about80%-85%are non-small cell lung cancer (NSCLC), while about70%of patients when they were diagnosed had been developed into advanced period. Therefore, the role of chemotherapy in the treatment of advanced NSCLC has become more and more important. Out of its wide adaptation, small side effects, Gemcitabine was approved by the U.S. FDA as the first-line NSCLC chemotherapy. Nevertheless, gemcitabine monotherapy in advanced NSCLC is still far from efficient. The main reason for the treatment failure is drug resistance. Many studies have shown that drug resistant is related to high expression of certain protein.Objective:By using matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)-MS, the aim of this study is to analyze the differences in the serum peptide levels of patients with non-small cell lung cancer (NSCLC) divided in two groups:group A (sensitive to gemcitabine) and group B (non-sensitive to gemcitabine), and to explore potential predictive factors for the efficacy of gemcitabine therapy in non-small cell lung cancer.Methods:1. During the period from March2012to September2013, twenty serum samples were collected from20advanced NSCLC patients that would be treated by gemcitabine in Shanxi Medical University the1st affiliated hospital. All these patients should be with at least one measurable tumor through imageological examination, with normal blood routine and blood biochemistry, and with no failure of any important organ. After2cycles’therapy, according to Response Evaluation Criteria in Solid Tumors,20samples were divided into two groups: effective group (CR+PR+SD) and non-effective group (PD).2. All blood samples were pre-separated by WCX microbeads, and then detected on the MALDI-TOF-MS platform of Bruker AutoflexTM. ClinProTools was used to analyze the differentially expressed proteins.Results:There were3protein peaks (m/z),5263.98、3096.38and16634.06found statistically differentially expressed between the effective group and non-effective group. All the three proteins were up-regulated.Conclusion:The data above suggest that several specific protein peaks might indicate gemcitabine resistance, yet the identities of these proteins and the mechanisms underlying the responsiveness to gemcitabine treatment need further investigation.